results

1 Introduction Kidney transplantation from a living donor is the treatment of choice for end-stage kidney disease, and currently represents 40% of all kidney transplantations (Hanson et al., 2019). To …

82% (n=9/11) of patients who received felzaltamab experienced resolution of symptoms. Antibody-mediated rejection The proportion of patients meeting the Banff criteria in the 24-week biopsy was significantly increased compared to …

A retrospective cohort study found that patients receiving kidneys from donors on dialysis were at significantly higher risk of delayed graft function (DGF) but had no long-term differences in graft …

The study evaluated the safety and tolerability of felzalutamab in adults who experienced late AMR at least six months after kidney transplantation. Credit: mi_viri / Shutterstock.com Human Immunology Biosciences (HI-Bio) …

As previously observed, our results suggest that, considered as a whole, the psychosocial status of LKD remains stable after donation3, 9, 30, 31. Few adverse psychosocial outcomes following donation were …